Clinical Trial Update: A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immune response of GSK's RSV vaccine candidate in Japanese older adults has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV vaccine candidate

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED | Results posted: 2022-02-25